# Synthesis Capital

> Synthesis Capital is a VC fund backing Food and Beverage and Biotechnology. See 12 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: London, United Kingdom
- Total investments: 12
- Last investment: Feb 2024
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/synthesiscapital
- Website: http://www.synthesis.capital

Synthesis Capital is an investment manager transforming our food system through food technology.

## Contacts

5 contacts available for Synthesis Capital. Shizune tracks 2 team members at Synthesis Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/synthesis-capital-6f8f?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $7.1M–$9M |
| Series A | $20M–$23M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Food and Beverage | 7 | 58% |
| Biotechnology | 6 | 50% |
| Food Processing | 5 | 42% |
| Organic Food | 3 | 25% |
| Sustainability | 3 | 25% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 3 | 25% |
| Seed | 2 | 17% |
| Series A | 2 | 17% |
| Venture - Series Unknown | 2 | 17% |
| Series B | 1 | 8% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 7 | 58% |
| Israel | 2 | 17% |
| Austria | 1 | 8% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Constantinos Yiannoulis | Managing Partner and Co - Founder | 3 | https://shizune.co/investors/profile/costa-yiannoulis |
| Rosie Wardle | Co-Founder and Partner | 4 | https://shizune.co/investors/profile/rosie-wardle |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Savor | Savor is transforming how fats and oils are produced for food. By using carbon-based feedstocks like CH4 and CO2, they create animal-equivalent alternatives that aim to decarbonize the 7% of global greenhouse gas emissions tied to traditional fat and oil production. Their first product, an animal-free butter launched in 2025 and is alreadygenerating excitement among chefs and food industry leaders. | $23M | Series A | Feb 09, 2024 |  |
| Triplebar | Triplebar provides sustainability, biotechnology, and synthetic biology research. |  |  | Oct 25, 2023 |  |
| Triplebar | Triplebar provides sustainability, biotechnology, and synthetic biology research. | $20M | Series A | Oct 25, 2023 |  |
| Hyfé | Hyfé Foods is a biotech company producing ingredients by leveraging fungal fermentation to upcycle water byproducts from food manufacturers. | $9M | Seed | Jun 22, 2023 |  |
| Equinom | Equinom is a fully integrated food-tech company, combining agricultural know-how, culinary expertise, and deep technology to develop delicious, nutritious, affordable, and sustainable non-GMO plant-based ingredients – from the ground up.For decades, crops have been farmed primarily for animal feed – not for human consumption. To be palatable inhuman food, these crops require extensive and expensive processing. . With limited processing facilities equipped for this use, the industry is on track to supply only 50% of the projected demand for plant-based foods.What is Equinom doing about it? Equinom is using science and technology to develop superior ingredients naturally, at the source – in a fraction of the time typically required to breed new crops. Equinom crops are bred naturally, without genetic editing or modification, and are optimized to make meat and dairy analogs more delicious, nutritious, cost-effective, and sustainable. The company’s proprietary Manna™ technology platform uses AI to speed the development of superior, high-yield, non-GMO ingredients as nature intended – featuring quality traits that satisfy consumer expectations. The technology also ensures biodiversity and climate resilience which are critical to ensure food security in light of climate change. Working with great partners including Meatless Farm, Roquette with GoodMills Group., Equinom is recognized as a trusted developer and supplier of unrivaled ingredients. Prestigious strategic investors such as BASF and Roquette have helped position Equinom as one of the breakout Round C companies to fuel the worldwide surge in plant-based eating. | $35M | Series D | Dec 12, 2022 |  |
| Mozza | Mozza engages in developing the science to create real dairy cheese from plants. Its mission is to make cheese from plants that are indistinguishable from cheese that comes from animals. The company was founded in 2018 and is headquartered in Los Angeles, California. | $9.4M | Venture - Series Unknown | Jun 14, 2022 |  |
| UPSIDE Foods | UPSIDE Foods (formerly known as Memphis Meats) develops meat produced directly from animal cells without the need to raise and slaughter actual animals. This approach requires significantly less water, land, and energy than conventional meat production, enabling consumers to enjoy meat that is clean, humane, and free of harmful chemicals.Co-founded and led by Dr. Uma Valeti in 2015, UPSIDE Foods is headquartered in Berkeley, California. | $400M | Series C | Apr 21, 2022 |  |
| Arkeon Biotechnologies | Arkeon Bio is a biotechnology company that captures CO2 from industry and converts inorganic gases into organic food. | $7.1M | Seed | Mar 04, 2022 |  |
| Redefine Meat | Redefine Meat uses 3D printing technology, meat digital modeling, and food formulations to produce animal-free meat. Redefine Meat technology produces animal-free meat with the same appearance, texture, and flavor of animal meat, from natural and sustainable ingredients. It was founded in 2018 and headquartered in Tel Aviv, Israel. | $135M | Venture - Series Unknown | Jan 23, 2022 |  |
| Culture Biosciences | Culture Biosciences provides a platform of cloud-connected bioreactors, software tools, and process development services that support upstream bioprocess development for biotech and biopharma applications. The company’s offerings include remote experiment design, monitoring, and data analysis through an integrated cloud software interface pairedwith single-use bioreactors for microbial fermentation and cell culture experimentation. Its services encompass clone and strain screening, process optimization, characterization, and bioprocess modeling to help scientific teams refine and scale their workflows. Clients access real-time data and analytics to inform decisions and collaborate across teams using the platform’s tools. Culture Biosciences’s technology is used to advance development of therapeutics, synthetic biology products, and related bioprocesses. Culture Biosciences was founded in 2016 and is headquartered in San Francisco, California. | $80M | Series B | Oct 14, 2021 |  |

10 of 12 investments shown.

## Co-investors
- [CPT Capital](https://shizune.co/investors/profile/cpt-capital) — VC Fund, 3 deals together
- [Stray Dog Capital](https://shizune.co/investors/profile/stray-dog-capital) — VC Fund, 3 deals together
- [The Production Board (TPB)](https://shizune.co/investors/profile/the-production-board-tpb) — VC Fund, 3 deals together
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund, 2 deals together
- [Cultivian Sandbox Ventures](https://shizune.co/investors/profile/cultivian-sandbox-ventures) — VC Fund, 2 deals together
- [iSelect Fund](https://shizune.co/investors/profile/iselectfund) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

### Similar country
- [Speedinvest](https://shizune.co/investors/profile/speedinvest) — VC Fund
- [tecnet equity](https://shizune.co/investors/profile/tecnet-equity) — VC Fund
- [aws Gründungsfonds](https://shizune.co/investors/profile/aws-grnderfonds) — VC Fund

## Featured in investor lists
- [Food and Beverage Investors in Austria](https://shizune.co/investors/food-and-beverage-investors-austria)
- [Food and Beverage VC Funds in Austria](https://shizune.co/investors/food-and-beverage-vc-funds-austria)
- [Organic Food Investors in Austria](https://shizune.co/investors/organic-food-investors-austria)
- [Biotechnology VC Funds in Austria](https://shizune.co/investors/biotechnology-vc-funds-austria)
- [Biotech Investors in Austria](https://shizune.co/investors/biotech-investors-austria)
- [Biotech VC Funds in Austria](https://shizune.co/investors/biotech-vc-funds-austria)

## FAQ

### What does Synthesis Capital invest in?

Synthesis Capital invests primarily in Food and Beverage, Biotechnology and Food Processing startups, most often at Series C and Seed stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Synthesis Capital's check size?

Synthesis Capital typically joins rounds of $7.1M–$9M at Seed and $20M–$23M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Synthesis Capital participates in.

### How do I contact Synthesis Capital?

Public channels for Synthesis Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Synthesis Capital?

The team at Synthesis Capital includes Constantinos Yiannoulis (Managing Partner and Co - Founder) and Rosie Wardle (Co-Founder and Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co